Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Atyr Pharma Inc (LIFE) Ordinary Shares

Sell:$3.72 Buy:$3.95 Change: $0.07 (1.92%)
NASDAQ:0.73%
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$3.72
Buy:$3.95
Change: $0.07 (1.92%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$3.72
Buy:$3.95
Change: $0.07 (1.92%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Contact details

Address:
3545 John Hopkins Ct Ste 250
SAN DIEGO
92121-1115
United States
Telephone:
+1 (858) 7318389
Website:
www.atyrpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LIFE
ISIN:
US0021202025
Market cap:
$15.06 million
Shares in issue:
3.89 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • John Clarke
    Independent Chairman of the Board
  • Sanjay Shukla
    President, Chief Executive Officer, Chief Medical Officer
  • Jill Broadfoot
    Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  • Grove Matsuoka
    Senior Vice President, Product Programs and Planning
  • Ashraf Amanullah
    Vice President, Biologics Development and Manufacturing

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.